Stephen Davis - 04 Jan 2022 Form 4 Insider Report for BELLICUM PHARMACEUTICALS, INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 04 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2022, 08:31:41 UTC
Prior SEC filing: 23 Dec 2021
Next SEC filing: 10 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Richard A. Fair, Attorney-in-Fact

Key filing fact

Stephen Davis filed Form 4 for BELLICUM PHARMACEUTICALS, INC on 06 Jan 2022.

Key facts

This page summarizes Stephen Davis's Form 4 filing for BELLICUM PHARMACEUTICALS, INC.
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2022, 08:31.

Change

Previous filing in this sequence was filed on 23 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLCM transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +18,715
Change %
Price: $0.000000
Shares after: 18,715
Date: 04 Jan 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLCM transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -18,715
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 04 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,715
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock.

Footnote F2

The RSUs vest in full upon the one year anniversary of grant date on January 4, 2021.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .